Matthew B. Klein, M.D., M.S., F.A.C.S.
Verkställande direktör (CEO)
Dr. Klein has been our Chief Executive Officer since March 2023. Dr. Klein joined the Company in October 2019 as Global Head, Gene and Mitochondrial Therapies and became Global Head, Clinical Development in March 2020, Chief Development Officer in April 2020 and Chief Operating Officer in January 2022. He also serves as a director of PTC Therapeutics International Limited, our international headquarters and indirect wholly-owned subsidiary. Prior to joining the Company, Dr. Klein was Chief Executive Officer of BioElectron from 2018 to 2019, and served as a member of the board of directors of BioElectron from 2018 to 2020. Dr. Klein served as the Chief Medical Officer of BioElectron from 2013 to 2019 and was Senior Vice President, Clinical Science at BioElectron from 2012 to 2013. Dr. Klein has also served as a member of the board of directors of ClearPoint Neuro, Inc., a Nasdaq listed company, since 2020 as our director designee. Dr. Klein has a BA from the University of Pennsylvania, an MD from Yale University School of Medicine and an MS in epidemiology from the University of Washington School of Public Health.
Matthew B. Klein, M.D., M.S., F.A.C.S. Verkställande direktör (CEO)Jag är oerhört stolt över att få leda PTCs erfarna och engagerade team in i de nästkommande 25 åren, när vi fortsätter att driva vår banbrytande vetenskap framåt för att utveckla värdefulla och transformerande behandlingar för både barn och vuxna med ouppfyllda medicinska behov. Vi kommer att fördjupa PTCs orubbliga åtaganden gentemot patienter, och driva en ansvarsfull företagstillväxt baserat på vår robusta produktportfölj, vår globala kommersiella infrastruktur och våra unika styrkor inom vetenskap och läkemedelsutveckling.
